This is unsurprising as healthcare costs remain a top concern—but national coverage doesn’t guarantee low costs and easy access.
It signals how the FDA may interpret tone, framing, and context in social media pharma marketing.
Most US adults monitor a health metric daily, but simpler, outcome-focused tracking may be more appealing.
AdWeek NY panelists urge pharma marketers to adapt as patients’ digital research increasingly shapes treatment decisions and informs conversations with doctors.
In today’s podcast episode, we discuss how the use of AI in healthcare has evolved in recent years, which part of the patient care journey AI is impacting the most, and the role of doctors in an AI-driven world. Join Senior Director of Podcasts and host Marcus Johnson, along with Senior Analysts Rajiv Leventhal and Beth Snyder Bulik. Listen wherever you get your podcasts, or watch on YouTube or Spotify.
AI prescribing models rolling out in Utah may make care more accessible—or show that AI medicine needs firmer limits.
Drug prices still surprise many consumers at the pharmacy counter, leading to delayed or abandoned prescriptions.
But content that explains conflicting clinical and AI guidance is essential for patient trust.
Genentech and Breastcancer.org highlight the need for more consistent patient follow-up during hormone therapy.
Consumers are still spending on the category, creating opportunities for retailers to weave wellness across assortments.
In August 2026, we analyzed 4,680 ChatGPT recommendations across 20 consumer health categories to compile the AI Visibility Index.
The $8B deal gives rivals an early view of four novel drugs to follow the duo’s blockbuster drug, Dupixent.
Walgreens will close fewer stores, but it still must adapt to changing shopping habits and give consumers more reasons to visit.
More Medicare Advantage enrollees will be redirected to switch plans next year, making proactive coverage communications essential.
Funding and coverage remain barriers—models that track use and outcomes can support future investment.
Oura pauses its public debut. Tough market conditions could sharpen questions about its valuation and room to expand.
But patients combine AI with familiar resources, so the most credible brand content will inform decisions.
Pharma is still interested in China-developed drugs amid US scrutiny and competition.
AI-powered triage and routine care would free up clinician capacity, but diagnostic tools without human intervention will face resistance.
AI health use is influencing care decisions and health product purchases. Structured pricing, availability, and eligibility data can help brands surface in AI results.